(TXG) 10X Genomics - Overview

Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 2.938m USD | Total Return: 202.2% in 12m

Instruments, Consumables, Software, Analysis
Total Rating 49
Safety 30
Buy Signal -0.01
Health Information Services
Industry Rotation: -24.5
Market Cap: 2.94B
Avg Turnover: 43.2M USD
ATR: 5.64%
Peers RS (IBD): 95.0
Risk 5d forecast
Volatility67.1%
Rel. Tail Risk-6.58%
Reward TTM
Sharpe Ratio1.74
Alpha157.49
Character TTM
Beta1.878
Beta Downside1.898
Drawdowns 3y
Max DD88.66%
CAGR/Max DD-0.28
EPS (Earnings per Share) EPS (Earnings per Share) of TXG over the last years for every Quarter: "2021-03": -0.11, "2021-06": -0.1, "2021-09": -0.15, "2021-12": -0.16, "2022-03": -0.38, "2022-06": -0.57, "2022-09": -0.37, "2022-12": -0.15, "2023-03": -0.44, "2023-06": -0.53, "2023-09": -0.79, "2023-12": -0.41, "2024-03": -0.5, "2024-06": -0.32, "2024-09": -0.02, "2024-12": -0.14, "2025-03": -0.28, "2025-06": 0.28, "2025-09": -0.0228, "2025-12": 0.0705, "2026-03": 0,
EPS CAGR: 37.27%
EPS Trend: 71.6%
Last SUE: 1.43
Qual. Beats: 2
Revenue Revenue of TXG over the last years for every Quarter: 2021-03: 105.821, 2021-06: 115.842, 2021-09: 125.297, 2021-12: 143.53, 2022-03: 114.496, 2022-06: 114.609, 2022-09: 131.072, 2022-12: 156.232, 2023-03: 134.285, 2023-06: 146.819, 2023-09: 153.644, 2023-12: 183.979, 2024-03: 141.006, 2024-06: 153.104, 2024-09: 151.654, 2024-12: 165.021, 2025-03: 154.883, 2025-06: 172.908, 2025-09: 149.002, 2025-12: 166.03, 2026-03: null,
Rev. CAGR: 10.42%
Rev. Trend: 70.6%
Last SUE: 0.21
Qual. Beats: 0

Warnings

High Debt/EBITDA (25.2) with thin interest coverage (-4118.0)

Interest Coverage Ratio -4118.0 is critical

Altman Z'' -8.03 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: TXG 10X Genomics

10x Genomics, Inc. (TXG) develops and sells instruments, consumables, and software for biological analysis globally. The company operates in the life sciences tools and services sector, which provides essential research technologies to a broad scientific community.

Its product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial analysis, and the Xenium Analyzer for in situ RNA detection. These platforms are used by academic, government, and biopharmaceutical institutions for advanced biological research.

The business model relies on selling both capital equipment (instruments) and recurring revenue consumables (reagents, kits, microfluidic chips), alongside proprietary software for data analysis. Interested readers can find more detailed financial metrics and competitive analysis on ValueRay.

Headlines to Watch Out For
  • Single cell and spatial analysis platform sales drive revenue growth
  • Increased adoption of Xenium platform boosts instrument and consumable demand
  • Research and development spending impacts profitability and innovation pipeline
  • Competition from established and emerging biotech companies intensifies
  • Regulatory changes in life science research affect product development and sales
Piotroski VR‑10 (Strict) 3.5
Net Income: -43.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 13.23 > 1.0
NWC/Revenue: 82.60% < 20% (prev 76.42%; Δ 6.19% < -1%)
CFO/TA 0.13 > 3% & CFO 136.1m > Net Income -43.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.46 > 1.5 & < 3
Outstanding Shares: last quarter (127.1m) vs 12m ago 4.51% < -2%
Gross Margin: 69.05% > 18% (prev 0.68%; Δ 6.84k% > 0.5%)
Asset Turnover: 65.59% > 50% (prev 66.49%; Δ -0.89% > 0%)
Interest Coverage Ratio: -4.12k > 6 (EBITDA TTM -12.5m / Interest Expense TTM 6.00k)
Altman Z'' -8.03
A: 0.51 (Total Current Assets 684.5m - Total Current Liabilities 153.5m) / Total Assets 1.04b
B: -1.45 (Retained Earnings -1.51b / Total Assets 1.04b)
C: -0.03 (EBIT TTM -24.7m / Avg Total Assets 980.0m)
D: -6.16 (Book Value of Equity -1.51b / Total Liabilities 245.0m)
Altman-Z'' Score: -8.03 = D
Beneish M -2.36
DSRI: 0.89 (Receivables 82.5m/87.9m, Revenue 642.8m/610.8m)
GMI: 0.98 (GM 69.05% / 67.86%)
AQI: 2.53 (AQ_t 0.07 / AQ_t-1 0.03)
SGI: 1.05 (Revenue 642.8m / 610.8m)
TATA: -0.17 (NI -43.5m - CFO 136.1m) / TA 1.04b)
Beneish M-Score: -2.36 (Cap -4..+1) = BBB
What is the price of TXG shares? As of April 11, 2026, the stock is trading at USD 23.27 with a total of 1,730,425 shares traded.
Over the past week, the price has changed by +6.30%, over one month by +13.73%, over three months by +17.53% and over the past year by +202.21%.
Is TXG a buy, sell or hold? 10X Genomics has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold TXG.
  • StrongBuy: 5
  • Buy: 2
  • Hold: 9
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the TXG price?
Analysts Target Price 20.6 -11.4%
10X Genomics (TXG) - Fundamental Data Overview as of 11 April 2026
P/E Forward = 208.3333
P/S = 4.5709
P/B = 3.5839
Revenue TTM = 642.8m USD
EBIT TTM = -24.7m USD
EBITDA TTM = -12.5m USD
Long Term Debt = 84.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 11.0m USD (from shortTermDebt, last quarter)
Debt = 157.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -316.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.57b USD (2.94b + Debt 157.7m - CCE 523.4m)
Interest Coverage Ratio = -4.12k (Ebit TTM -24.7m / Interest Expense TTM 6.00k)
EV/FCF = 19.77x (Enterprise Value 2.57b / FCF TTM 130.1m)
FCF Yield = 5.06% (FCF TTM 130.1m / Enterprise Value 2.57b)
FCF Margin = 20.24% (FCF TTM 130.1m / Revenue TTM 642.8m)
Net Margin = -6.77% (Net Income TTM -43.5m / Revenue TTM 642.8m)
Gross Margin = 69.05% ((Revenue TTM 642.8m - Cost of Revenue TTM 198.9m) / Revenue TTM)
Gross Margin QoQ = 68.09% (prev 67.32%)
Tobins Q-Ratio = 2.47 (Enterprise Value 2.57b / Total Assets 1.04b)
Interest Expense / Debt = 0.00% (Interest Expense 3.00k / Debt 157.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -19.5m (EBIT -24.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.46 (Total Current Assets 684.5m / Total Current Liabilities 153.5m)
Debt / Equity = 0.20 (Debt 157.7m / totalStockholderEquity, last quarter 796.3m)
 Debt / EBITDA = 25.23 (negative EBITDA) (Net Debt -316.2m / EBITDA -12.5m)
 Debt / FCF = -2.43 (Net Debt -316.2m / FCF TTM 130.1m)
Total Stockholder Equity = 765.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.44% (Net Income -43.5m / Total Assets 1.04b)
RoE = -5.69% (Net Income TTM -43.5m / Total Stockholder Equity 765.4m)
RoCE = -2.91% (EBIT -24.7m / Capital Employed (Equity 765.4m + L.T.Debt 84.4m))
 RoIC = -2.55% (negative operating profit) (NOPAT -19.5m / Invested Capital 765.4m)
 WACC = 11.95% (E(2.94b)/V(3.10b) * Re(12.59%) + D(157.7m)/V(3.10b) * Rd(0.00%) * (1-Tc(0.21)))
Discount Rate = 12.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.53%
[DCF] Terminal Value 55.11% ; FCFF base≈130.1m ; Y1≈85.4m ; Y5≈39.1m
[DCF] Fair Price = 6.63 (EV 464.0m - Net Debt -316.2m = Equity 780.3m / Shares 117.7m; r=11.95% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 71.62 | EPS CAGR: 37.27% | SUE: 1.43 | # QB: 2
Revenue Correlation: 70.58 | Revenue CAGR: 10.42% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.05 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-12-31): EPS=-0.13 | Chg7d=+0.003 | Chg30d=+0.003 | Revisions Net=+0 | Growth EPS=-208.3% | Growth Revenue=-4.6%
EPS next Year (2027-12-31): EPS=0.17 | Chg7d=+0.003 | Chg30d=+0.003 | Revisions Net=-1 | Growth EPS=+225.0% | Growth Revenue=+7.5%
External Resources
Dataroma Stockcircle